KR20240012380A - 지향 접합 기술용 제제 및 접합 생성물 - Google Patents

지향 접합 기술용 제제 및 접합 생성물 Download PDF

Info

Publication number
KR20240012380A
KR20240012380A KR1020237039500A KR20237039500A KR20240012380A KR 20240012380 A KR20240012380 A KR 20240012380A KR 1020237039500 A KR1020237039500 A KR 1020237039500A KR 20237039500 A KR20237039500 A KR 20237039500A KR 20240012380 A KR20240012380 A KR 20240012380A
Authority
KR
South Korea
Prior art keywords
moiety
independently
compound
interest
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237039500A
Other languages
English (en)
Korean (ko)
Inventor
비슬라프 카즈미에르스키
진 엠. 두보치크
리즈 엠. 콜드웰
데이비드 애덤 스피겔
Original Assignee
바이오하벤 테라퓨틱스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오하벤 테라퓨틱스 리미티드 filed Critical 바이오하벤 테라퓨틱스 리미티드
Publication of KR20240012380A publication Critical patent/KR20240012380A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237039500A 2021-05-17 2022-05-17 지향 접합 기술용 제제 및 접합 생성물 Pending KR20240012380A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163189522P 2021-05-17 2021-05-17
US63/189,522 2021-05-17
PCT/US2022/029535 WO2022245759A2 (en) 2021-05-17 2022-05-17 Agents for directed conjugation techniques and conjugated products

Publications (1)

Publication Number Publication Date
KR20240012380A true KR20240012380A (ko) 2024-01-29

Family

ID=84140970

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237039500A Pending KR20240012380A (ko) 2021-05-17 2022-05-17 지향 접합 기술용 제제 및 접합 생성물

Country Status (11)

Country Link
US (1) US20240252674A1 (https=)
EP (1) EP4340891A4 (https=)
JP (1) JP2024519814A (https=)
KR (1) KR20240012380A (https=)
CN (1) CN117750979A (https=)
AU (1) AU2022275832A1 (https=)
CA (1) CA3219517A1 (https=)
IL (1) IL307799A (https=)
MX (1) MX2023013272A (https=)
PH (1) PH12023553154A1 (https=)
WO (1) WO2022245759A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3219475A1 (en) * 2021-05-17 2022-11-24 Wieslaw Kazmierski Compositions including conjugated therapy enhancers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7226577B2 (en) * 2003-01-13 2007-06-05 Bracco Imaging, S. P. A. Gastrin releasing peptide compounds
US20140079636A1 (en) * 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
PL3086814T3 (pl) * 2013-12-23 2020-12-28 Bayer Pharma Aktiengesellschaft Koniugaty środka wiążącego (ADC) z inhibitorami KSP
WO2017042944A1 (ja) * 2015-09-10 2017-03-16 国立大学法人山梨大学 フィラデルフィア染色体陽性（Ｐｈ＋）急性リンパ性白血病（ＡＬＬ）の治療薬又は治療方法
EP3617235B1 (en) * 2017-04-28 2026-02-18 Ajinomoto Co., Inc. Compound having substance that has affinity for soluble protein, cleavable moiety, and reactive group, or salt thereof
MX421628B (es) * 2017-07-26 2025-03-14 Kleo Pharmaceuticals Inc Compuestos abt universales y usos de los mismos
JP7404230B2 (ja) * 2017-09-18 2023-12-25 トラスティーズ オブ ボストン ユニバーシティ ネトーシスおよび好中球活性化を処置するための方法
WO2019241609A1 (en) * 2018-06-15 2019-12-19 Trustees Of Boston University Polypeptide compositions and methods for site-specific targeting of therapeutic agents
AU2020299157A1 (en) * 2019-07-03 2022-01-20 Kleo Pharmaceuticals, Inc. CD38-binding agents and uses thereof

Also Published As

Publication number Publication date
WO2022245759A3 (en) 2023-02-02
MX2023013272A (es) 2023-11-30
AU2022275832A1 (en) 2023-12-14
US20240252674A1 (en) 2024-08-01
CN117750979A (zh) 2024-03-22
WO2022245759A2 (en) 2022-11-24
CA3219517A1 (en) 2022-11-24
IL307799A (en) 2023-12-01
PH12023553154A1 (en) 2024-03-11
JP2024519814A (ja) 2024-05-21
EP4340891A4 (en) 2025-07-02
EP4340891A2 (en) 2024-03-27

Similar Documents

Publication Publication Date Title
JP7221259B2 (ja) 改変した抗体組成物、それを作製および使用する方法
CA3066920C (en) COMPOUNDS OF MODIFIED ANTIBODY AND CONJUGATES OF THESE
KR102511249B1 (ko) 신규한 안정한 항체-약물 복합체, 이의 제조방법 및 이의 용도
JP5861223B2 (ja) プロタンパク質およびその使用方法
JP6215056B2 (ja) 拮抗性ｄｒ３リガンド
CN103748222B (zh) 新型抗人ngf抗体
JP2019523214A (ja) Ｍｔ１−ｍｍｐに対して特異的な二環式ペプチド−毒素コンジュゲート
JPWO2018230257A1 (ja) ＩｇＧ結合ペプチド、及び該ペプチドによる抗体の特異的修飾
JP2012511033A (ja) 多価化合物の可逆阻害用マスキングリガンド
EA017690B1 (ru) Мутанты fgf21 и их применение
JP2010534486A (ja) 新規な組成物、方法および使用
KR20130050966A (ko) 다기능적 항체 접합체
CN102665768A (zh) 肽清除剂
WO2019127346A1 (zh) 募集抗体并靶向肿瘤细胞的双功能分子
KR20240012380A (ko) 지향 접합 기술용 제제 및 접합 생성물
JP6583411B2 (ja) 薬物複合体
US20240247076A1 (en) Coagulation factor xi (fxi) binding protein
KR20240012376A (ko) 접합된 치료 강화제를 포함하는 조성물
US20240156974A1 (en) Compositions and methods for modulation of antibody activity
Plumpton et al. Site‐directed monoclonal antibodies against the amino terminus of 124‐kDa phytochrome from Avena sativa L.
CN118255900A (zh) 具有抗体募集功能的fgfr1拮抗肽衍生物及其合成和抗肿瘤应用
JP2025528776A (ja) 血液脳関門を通過するための抗体ベースの構造体のｂｂｂシャトルによる部位特異的修飾
HK1188384A (en) Multifunctional antibody conjugates

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000